Biomarin Pharmaceutical Inc.
|
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises three products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride) and Aldurazyme (laronidase). As on December 31, 2007, BioMarin was conducting clinical trials on several product candidates for the treatment of genetic diseases, including PEG-PAL, formerly referred to as Phenylase (phenylalanine ammonia lyase), an enzyme substitution therapy for the treatment of phenylketonurics who are not responsive to Kuvan. On January 3, 2008, the Company purch...
More from Zoominfo » |
BioMarin & La Jolla enter agreement to develop & commercialize Riquent
BioMarin Pharmaceutical Inc and La Jolla Pharmaceutical Company have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region.
From PharmaBiz - 51 minutes ago
BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14th, 2009 at 11:00 a.m.
From PR Newswire via Yahoo! Finance - 14 hours ago
BioMarin May Spend $289 Million for La Jolla’s Drug
Jan. 6 (Bloomberg) -- BioMarin Pharmaceutical Inc. agreed to pay as much as $289 million to La Jolla Pharmaceutical Co. for Riquent, an experimental treatment for the autoimmune disease lupus that has failed in two earlier studies.
From Update2 - 1 day ago
More news from Yahoo! News
|
|
|
